Gestational Diabetes Follow Up Study

Diabetes, Gestational Clinical Trial

Official title:

Es Mejor Saber: A Proactive Approach to Gestational Diabetes Follow Up

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00998595
• Other study ID #: MM-1107-09/09 (AAMC-CDC)
• Status: Completed
• Phase: N/A
• First received: October 19, 2009
• Last updated: March 29, 2017
• Start date: June 2009
• Est. completion date: October 2011

Study information

• Verified date: September 2011
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary hypothesis underlying this proposal is that the introduction of a Promotora to provide education and proactive follow-up to women with GDM will increase compliance with postpartum glucose tolerance testing. The secondary hypothesis is that the Promotora will improve participation in referral visits for diabetes or preventive care. We will develop the promotora program and begin pilot implementation.

Description:

As Los Angeles County + University of Southern California Medical Center (LAC+USC) serves an indigent Latino population at increased risk for developing Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus (GDM) complicated 13% of deliveries at LAC+USC between 2006-2007. While over 50% of GDM patients will develop overt diabetes mellitus within a decade of the incident pregnancy, less than half of these patients ever return for even one post-partum follow up visit at this institution (45%). Lifestyle Interventions and medications have been shown to delay or prevent the onset of T2DM. However, prevention is only possible if patients follow-up and individual risk assessment is made. While identifying the 2-hour glucose tolerance test as the appropriate postpartum screening technique for patients with a history of GDM, the Fifth International Workshop-Conference on Gestational Diabetes Mellitus did not identify strategies to improve follow up among this patient population. Promotoras (bi-lingual, bi-cultural lay community health workers representative of the Latino community base) have been successful in improving follow up for other areas of diabetes and women's preventive services but have not been studies in the context of GDM. We will develop the Es Mejor Saber training materials and program and pilot a randomized control trial (RCT),a total 216 subjects completing a GDM affected pregnancy will be randomized on the postpartum ward to the standard-of-care versus proactive follow-up with a Promotora. The Promotora will provide education, address barriers to follow-up, remind subjects of their appointments, and call them to reschedule if they miss appointments. In the first phase of the study, these appointments will include the OGTT and the initial postpartum visit. In the second phase, these visits will include referrals to internal medicine (for those diagnosed with T2DM) or nutrition counseling (for those found not to have diabetes). The primary hypothesis underlying this proposal is that the introduction of a Promotora providing education and pro-active follow-up into postpartum GDM management will result improve post-partum follow-up for screening, treatment, and preventive services when compared with the standard of care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. completion date: October 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with diabetes for the first time during the most recent pregnancy

• Completed pregnancy >20 weeks duration

• Has access to a telephone

• Is willing to be contacted by the Promotora

• Is willing to follow-up at LAC+USC for postpartum visit

• Able to give informed consent

• Age =18 years

• Residence within 60 miles of LAC+USC

• ON INPATIENT WARD AT LAC+USC AT TIME OF RECRUITMENT

Exclusion Criteria:

• Diagnosis of diabetes prior to most recent pregnancy (pre-gestational diabetes)

• Current ICU admission during delivery hospitalization that would interfere with recruitment and participation in the study

• Currently residing in jail or inpatient psychiatric facility

• Postpartum day #1-2, any Fasting Blood Glucose =126mg/dL or random BG=200mg/dL

• Plans postpartum follow-up at non-participating postpartum clinic location

A Medical Record Abstraction Only Cohort is a third group of patients who live within 60 miles of LAC+USC, plan to obtain postpartum care at LAC+USC, and completed a GDM affected pregnancy but refuse participation or do not qualify based on the following: elevated glucose consistent with diagnosis of T2DM or maintained on insulin postpartum, incarceration or resides in inpatient psychiatric facility, age <18, no telephone, unwilling to be contacted by Promotora, or are unable to consent for participation.This cohort can not be enrolled in the study but data is abstracted from the medical records to compare demographics and follow up in our study to all patients with GDM who deliver at LAC+USC.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes, Gestational
• Postpartum Period

Intervention

Other:
• Promotora
The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.

Locations

Country	Name	City	State
United States	Los Angeles County + University of Southern California Medical Center	Los Angeles	California

Sponsors (3)

Lead Sponsor	Collaborator
University of Southern California	Association of American Medical Colleges, Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the fraction of each group that participates in postpartum follow up and glucose tolerance testing 4-12 weeks post partum.		4-12 weeks post partum
Secondary	the fraction of women in each group that attends a referral visit		within 8 weeks following referral